Booth #717 / #719
Visit the Sartorius booth at PEGS Boston to learn the latest on the Intellicyt iQue® Screener PLUS and the IncuCyte® S3 Live-Cell Analysis System. These innovative cell analysis systems provide specialized instrumentation, software and reagents to accelerate discovery and development of novel therapeutics and provide new insight into the mechanisms of disease at a speed, depth and scale not achievable with conventional cell analysis techniques.
- Multiplexed binding assays (96-well plate in 5 min)
- Identify targets in their native conformation
- Evaluate specificity and species cross-reactivity in the same well
- Get information on cell health, isotype and titer from a single assay
- Derive kinetic, image-based measurements from inside your incubator
- Real-time monitoring of cell health and viability, migration and invasion, and other phenotypic cell-based assays
- Profile cell-specific and time-dependent biological activity
- Powerful imaging & analysis tools for real-time decision-making
In addition, learn about Sartorius’ Platform in a Briefcase, our process development strategy that enables you to save time and resources from taking drugs from the bench to the clinic. Platform in a Briefcase offers innovative technologies and solutions for all parts of the process, from cell line development to product characterization, to fill and finish.
At the show, please visit our poster presentation.
Development of a High-Throughput Multiplex Mouse IgG Isotyping and Quantitation Assay
Presenter: Mark Carter, Senior Assay Consulting Scientist
Date and Time: Poster Session B – Wednesday, May 2 10:10 AM – 7:00 PM and Thursday, May 3 10:05 AM – 1:40 PM
Authors: Mark Carter, John O’Rourke, and Zhaoping Liu
Intellicyt Corporation, Part of the Sartorius Group. 5700 Pasadena Ave. NE, Albuquerque, NM 87113
Monoclonal antibodies are the fastest-growing class of therapeutic agents with success in treating a wide range of diseases such as cancer, cardiovascular disease, autoimmune disorders and infectious disease. Most therapeutic antibody candidates are initially generated from mouse hybridomas or primary B cell clones after antigen immunization. In the antibody discovery workflow, primary screens identify clones with specific attributes that are assessed for a variety of critical parameters such as IgG isotyping, antibody quantification, and cell health metrics, which is vital information for lead molecule generation.
Quantification of mouse antibody from cell culture supernatant is traditionally assessed using enzyme-linked immunosorbent assay (ELISA). Additionally, separate IgG isotyping and cell count/health assays are performed to facilitate and optimize cloning of antibody variable regions into the proper expression vector. To overcome limitations of these traditional assays, we developed a high throughput, multiplexed assay that expedites antibody discovery, identifying optimal clones for downstream processes.
This is a multiplex competition assay which uses isotype-specific beads in the same well to capture four mouse IgG isotypes (IgG1, 2a, 2b, 3) from the sample. This biochemistry achieves a wide dynamic range, reduces the need for sample dilution and eliminates wash steps. Our data shows that critical mouse antibody parameters can be assessed using a single, high throughput multiplex assay. The high-content data generated by this assay simplifies the antibody discovery workflow and reduces the time to make actionable decisions.